James William Rogers Sells 7,257 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 7,257 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total value of $475,623.78. Following the completion of the transaction, the chief financial officer owned 131,216 shares of the company’s stock, valued at $8,599,896.64. This trade represents a 5.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Performance

Tempus AI stock traded down $3.40 during trading hours on Thursday, hitting $65.69. 7,149,431 shares of the stock traded hands, compared to its average volume of 11,236,510. The firm’s 50 day moving average price is $84.42 and its 200-day moving average price is $71.91. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The stock has a market capitalization of $11.69 billion, a price-to-earnings ratio of -55.20 and a beta of 4.86. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company’s revenue was up 84.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.46) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the stock. Cranbrook Wealth Management LLC purchased a new position in Tempus AI in the 3rd quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in Tempus AI during the 3rd quarter worth approximately $26,000. GAMMA Investing LLC acquired a new position in shares of Tempus AI during the third quarter valued at approximately $28,000. Concord Wealth Partners lifted its position in shares of Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after acquiring an additional 308 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley upped their price target on shares of Tempus AI from $68.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. BTIG Research reiterated a “buy” rating and set a $96.00 price objective on shares of Tempus AI in a research note on Wednesday, November 5th. TD Cowen lowered Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price on the stock. in a report on Tuesday, October 21st. Finally, Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $80.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.